IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

A Concise Summary of Transdermal Patches

Ms. Vaishnavi Dhondiram Naikwade[1], Ms. Ankita Arjun Giramkar[2], Priti Amar Nagargoje[3], Prathamesh N Bansode[4], Ms. Rutuja N Raut[5].
Student, Department of Pharmaceutical Science[1]
Assistant Professor, Department of Pharmaceutical Science[2,3,4,5]
Saikrupa Institute of Pharmacy, Ghargaon, Ahmednagar, Maharashtra, India

Abstract: *Transdermal patches offer a method of drug delivery that does not require penetration of the skinIt is a patch with adhesive properties that releases a controlled amount of medication into the bloodstream via the skinTransdermal drug delivery offers numerous benefits when compared to alternative methods of administrationIt is less invasive, more patient-friendly, and can the harsh acidic condition of the stomach that drugs are exposed to when taken orallyTransdermal patches have been a focus of interest and have been utilized for many years to administer medication like nicotine, fentanyl, nitroglycerin, and clonidine for the treatment of different illnesses or ailmentsFor millennia, human societies have used various substances on the skin for cosmetic and medicinal purposesNevertheless, it wasn't until the 20th century that the skin started being utilized as a means of delivering drugsAccording to Merriam Webster, the fact is that the dates are The term "transdermal" was introduced in 1944, signifying its novelty in medical and pharmaceutical fieldsTransdermal medications come in self□contained, distinct dosage formDelivering drugs through the skin to produce a systemic impactwithout causing any variations in the drug's plasma levelsAdministering therapeutic agents topically provides numerous benefits compared to traditional oral and invasive drug delivery techniquesFurthermore, it allows for the controlled release of the medication for a prolonged period of timeThis review article briefly outlines the benefits and skin routes for transdermal drug deliverytransdermal drug delivery systems (TDDS), different parts of transdermal patch, and methods for creating transdermal patches Assessment of transdermal systems, overall clinical factors in the use of TDDS, and restrictions of TDDS*

Keywords: Transdermal, Permeation pathways, Drug delivery, Matrix, Reservoir

I. INTRODUCTION

Transdermal drug delivery systems (TDDS) are designed to deliver a therapeutic amount of medication through the skin of a patient, providing the necessary dose of the drug to the bodyTo achieve systemic effects through the skin for therapeutic substance delivery, it is crucial to thoroughly understand the biophysical, morphological, and physicochemical properties of the skinTransdermal drug administration offers significant benefits over injections and oral methods by enhancing patient adherence and bypassing initial metabolism.(1)

It guarantees a regulated and steady delivery of drugs, especially helpful for medications with quick biological half-lives, avoiding sudden introduction into the bloodstream that can cause negative side effectsConsequently, different advanced drug delivery systems, including Transdermal drug delivery systems, Transmucosal delivery systems, and Controlled release systems, have been createdAdvantages of transdermal drug administration involve enhanced treatment efficacy, decreased liver metabolism, and sustaining a consistent drug level in the bloodThe initial transdermal system received approval from the FDA in 1979 for the purpose of preventing nausea and vomitingConfirmation of percutaneous drug absorption can be confirmed by measuring blood levels, detecting excretion of the drug and its metabolites in urine, and observing the patient's clinical response to the drug therapy administered.(2)

A specialized medicated patch called a transdermal patch is designed to deliver drugs into the bloodstream at a controlled rate by penetrating the skin layersThese patches provide a very convenient way to administer drugs, as they are painless and can offer continuous treatment for multiple daysMoreover, they can be easily stopped whenever necessaryTransdermal patches come in different sizes and may include several active ingredients When these patches

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

are placed on the skin, they utilize diffusion mechanisms to transport the active ingredients directly into the bloodstreamCertain patches may have high concentrations of the active ingredient, which stays on the skin for a prolonged durationThe initial transdermal patch introduced in 1985 was Nitroglycerin, representing a notable advancement in drug delivery through the skinGale and Berggren created patches containing an ethylene vinyl acetate membrane that controls the release rateDifferent medications come in the form of patches that are applied to the skin, including nicotine, estradiol, fentanyl, clonidine, scopolamine (hyoscine), and estradiol with norethisterone acetateThe location for applying the patch depends on the type of medication being used.[3]

For example, estradiol patches are usually placed in the vicinity of the buttocks or abdomen, whereas nitroglycerin patches can be put around the chest regionThe length of time for drug release varies from 9 hours to 9 days, depending on the intended purpose

ADVANTAGES

- Transdermal delivery prevents first-pass metabolism by providing a substance to permeate continuously and steadily over a long period of time.[4]
- Promote higher levels of patient adherence.[5]
- It does not disrupt the liquid in the stomach and intestines.[6][7]
- Maintains consistent and steady blood levels, offering extended period control.
- Lower levels of drug concentration in the plasma.
- Minimize plasma level changes by using drugs with brief half-lives and narrow therapeutic indices.[8]
- If toxicity occurs, drug delivery can be quickly removed.
- Decreasing dosing frequency can improve patients' adherence.
- Transdermal administration improves the efficacy of many medications by avoiding specific problems associated with the drugs, like inadequate absorption and irritation in the gastrointestinal tract.
- The simplified drug regimen leads to less variation in drug reactions within and between patients.

DISADVANTAGES

- The drug needs to have good physicochemical properties in order to penetrate the stratum corneum.
- The drug amount should not exceed 5mg/day for daily doses; beyond 10-25 mg/day, transdermal drug delivery presents difficulties.
- The components in the patch, such as the medication, adhesive, and additional ingredients, may lead to local irritation.
- A definite clinical need must be outlined before using the transdermal delivery system.
- It was impossible to reach high levels of drugs in the blood/plasma.
- Drugs with a large molecular size are not able to be formulated.
- Chance of inflammation at the application site.[9]
- Uncomfortable to put on.
- May be uneconomical.
- The skin barrier differs among people and may also fluctuate in the same individual over time.

A BRIEF OVERVIEW OF TRANSDERMAL PATCHES/ITEMS AND THEIR DISTINGUISHING CHARACTERISTIC

Drugs	Indication	Product Name	Duration of Application	Reference
Asenapine	Mania, bipolar disorder	Secuado®	24 h	[9,10]
Bisoprolol	Atrial fibrillation	Bisono®	24 h	[11,12]
Buprenorphine	Management of pain	Butrans®	7 days	[13,14,15]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

Drugs	Indication	Product Name	Duration of Application	Reference
Clonidine	Hypertension, Tic disorder, Tourette syndrome, Attention deficit hyperactivity disorder (ADHD)	Catapres-TTS®	7 days	[16,17,18,19]
Dextroamphetamine	ADHD	Xelstrym®	Up to 9 h	[20]
Donepezil	Alzheimer disease	Adlarity®	7 days	[21,22]
Estrogen	Postmenstrual syndrome	Fematrix®	7 days	[23,24]
Ethinyl Estradiol	Prevent pregnancy	Ortho Evra®	7 days	[25,26]
Fentanyl	Moderate/severe pain	Duragesic®	72 hours	[27]
Granisetron	Anti-emetic	Sancuso®	Up to 7 days	[28,29,30]
Levonorgestrel, Estradiol	Postmenstrual syndrome	Climara Pro®	7 days	[31,32]
Lidocaine	Treatment of pain	Lidoderm® Dermalid®	up to 3 times daily for no more than 12 hours	[33,34]
Methylphenidate	ADHD	Daytrana®	Up to 9 days	[35]
Nicotine	Smoking cessation	Habitrol®, Nicoderm® Nicoderm CQ® Nicorette®	24 h 16 h	[36,37,38]
Nitroglycerin	Angina pectoris Relieve pain after surgery	Minitran® Nitro-dur®	12–14 h	[39,40,41,42]
Norethindrone Estradiol	Symptoms of menopause	Combipatch®	3–4 days	[43]
Oxybutynin	Overactive bladder	Oxytrol®	3–4 days	[44,45]
Rivastigmine	Alzheimer disease	Exelon®	24 h	[46,47]
Rotigotine	Parkinson's disease	Neupro®	24 h	[48]
Selegiline	Depression	Emsam®	24 h	[49]
Scopolamine	Motion sickness	Transderm-scop®	72 h	[50,51]
Testosterone	Hypogonadism in males	Androderm®	24 h	[52,53]
17-β-Estradiol	Postmenstrual syndrome and osteoporosis	Alora® Climara® Estraderm® Vivelle-Dot ® Vivella®	3–4 days 7 days 3–4 days 3–4 days 3–4 days	[54,55,56]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

Drugs	Indication	Product Name	Duration of Application	Reference
		Menostar®	7 days	
		Minivelle®	3–4 days	

MECHANISM OF ACTION OF TRANDERMAL PATCH

The application of the transdermal patch and the flow of the active drug constituent from the patch to the circulatory system via skin occur through various methods.



Figure 1

FUNCTIONS OT THE SKIN'S BIOLOGY:

The skin on a typical adult body spans a certain surface areaabout 2 square meters in size and gets around a third of the Blood moving throughout the bodySkin consists (figure 1)of a topmost layer called epidermis that contains different regions in terms of morphology; basal layer, spiny layer, stratum granulosum and outermost stratum corneum, it comprised of heavily keratinized (lifeless) cells trapped in a uninterrupted array of lipid layersTerms and conditions apply to all purchases made on this platformextracellular membranes have distinctive compositions consist of ceramides, cholesterol, and free fatty acids chemical substances that release hydrogen ions when dissolved in wateraverage, about 1 million bacteria per square centimeteron average, there are 10 to 70 hair follicles and 200 to 250 sweat ductseach square centimeter of the skin's surface areaIt is one of the utmosteasily reached parts of the human body[57,58]



Figure 2: Anatomical and physiological Structure of skin

TRANSDERMAL DRUG DELIVERY THROUGH SKIN PATHWAYS

Penetrance occurs when drugs are administered topicallyPenetration and passage through the skin may happen through different pathways Substances enter through the stratum corneum Through the epidermis, or through the skin

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

appendages(Figure 2) depictsWhile moving through the stratum In the outer layer of the skin, two different paths can be identifiedThe penetration moves back and forth between the corneocyteslipid lamellae (transcellular pathway) and ii) Infiltration through the winding path next to the lipid layers (between cells) path, way



Figure 3: Potential routes for drug diffusion through the protective layer of skin

It is generally acknowledged that the main way of penetrating through the stratum corneum is thepathway between cellsThis is predominantly the result of the high population densitykeratinocytes are covered by a cross-linked cornified envelopeYet, transcellular movement of small hydrophilic substancesSubstances like water cannot be entirely eliminatedThe pathway via appendage or shunt involves the ductof the eccrine sweat glands or the follicular ductsubtitle of the movie **is** "A Tale of Love and Loss"The primary composition of eccrine sweat glands is mostly water-lovingthe follicular duct's content is lipophilicThis represents primarily because of the sebum produced in the entrance of the duct of the hair follicleIt is widely acknowledged that because of its substantial passive skin permeation predominantly takes place on the surface area via unharmed outer layer of skin.[59-62]

ESSENTIAL ELEMENTS OF TOPICAL ADMINISTRATION SYSTEMS FOR DELIVERING DRUGS:

< Polymer material
< Medication
< Substances that increase permeability
< Additional ingredients

Polymer matrix:

The polymer manages the dispensing of the drug from the deviceFor a polymer to be used in Transdermal devices, it must meet the specified criteria.

Table 1: Showing different types of polymers

Natural polymers	Synthetic Elastomers	Synthetic polymers
Cellulose derivatives, Zein, Gelatin, Waxes, Proteins, Gums, Natural rubber, Starch.	Polybutadiene, Hydrin rubber, polysiloxane, silicone rubber, Nitrile, Acrylonitrile, Butylrubber, Styrenebutadiene, Neoprene etc	Polyethylene, Polypropylene, Polyacrylate, Polyamide, Polyvinylpyrrolidone, Polymethyl methacrylate, Epoxy, Polyurea, etc.

Medication:

To achieve successful development of a transdermal drug delivery system When selecting a drug, it is important to carefully consider the system it will interact withThe text must be paraphrased without changing the input language and keeping the word count the sameHere are a few of the desirable characteristics of a medicationDelivery through the skin

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

Characteristics of matter that relate to both physical and chemical aspects:

The medication needs to have a lower molecular weightless than about 1000 Daltons

The medication needs to exhibit a preference for both lipophilic substances and phases that are attracted to water Intense division traits do not support effective medication transportation through the skin.

The medication must possess a low melting temperature.

Biological Properties:

The medication needs to be strong when taken once a daya few milligrams per day.

The drug's half life (t1/2) should be brief.

The drug should not cause any irritation to the skinreaction to allergies.

Medications that break down in the gastrointestinal tract or become ineffective are appropriate choices for due to the hepatic first-pass effect.

Delivery through the skinResistance to the medication should not build up over time.

Transdermal delivery exhibiting zero-order release patternterm, can have negative side effects on the bodyperiod during which negative impacts are provoked on non..

Target tissues can also be structured for transdermal delivery

Substances that increase permeability

Permeation enhancers or promoters are substances that do not have any direct pharmacological activity but help in increasing the absorption of drugshave their own healing qualities but can also convey the absorption of medications from medication administration systems onto the SkinThe movement of medications through the skin[(11)] can be expressed as:

J=D Xdc/dx.

D, as the diffusion coefficient, varies with dimensions, form, and pliability of the dispersing molecule equally resistance of the membrane, with C representing the concentrationspreading substances; x represents the location dimension.

conditions is complex, it can be found by applying advanced mathematical techniquesVariations in conditions and differences in membrane composition can cause significant differencessophisticated, the fundamental ideas concerning improvement in flux is present in the equation provided aboveThe focus The origin of the gradient is thermodynamic, and it leads to diffusionCoefficient is connected to the dimensions and form of penetrationthe amount of energy needed to create an opening for diffusionIn this way increasing the flow through membranes is reduced to factors to consider:

Thermodynamics involves lattice energies and distribution(factors) in the same quantity

Size and configuration at the molecular level.

Decreasing the energy needed for producing a molecularan opening in the membrane.

It is hypothesized that permeation enhancers have an impact on oneTo reach skin penetration, one or multiple layers must be penetratedImprovementMany compounds exist in abundancere searched for their potential to improve stratum permeability of the stratum corneum These conveniently organized.

Summarize the text

Restate the text clearly

Explain the text in a different way

Solvents: these substances could enhance penetration, potentially through

Increasing the polar routes within the skin.

Lipids becoming fluidized.

Some instances are water, along with alcohols like methanol and ethanol.vmethyl sulfoxides like dimethyl sulfoxide, alkyl compounds similar to methyl sulfoxide, dimethyl acetamide and dimethyl formamide; 2-pyrrolidones of pyrrolidone; Azone, also known as laurocapram, along with other solvents like propyleneglycol, glycerol, fluids made from silicone, isopropyl palmitate.

Surfactant: These substances are suggested to improvetransport through a polar pathway, particularly for hydrophilic medicationsA surfactant's capacity to change penetration is determined by its effectivenessof the length of the

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

hydrocarbon chain and the head groupThese employees need to attend a mandatory training session next weekcompounds can irritate the skin, so achieving a equilibrium between improved penetration and irritation must be addressed ponderedAnionic surfactants have the ability to enter and engage withhaving a strong connection with the skinOnce these agents have When they enter the skin, they are capable of causing significant changesIt has been reported that cationic surfactants are more irritating than the restanionic surfactants have not been extensively researched for improving absorption through the skinThere are three main categories of nonionic surfactants have been known for a long time those who are least likely to cause annoyance and have been extensively researched.

Various surfactants are commonly used.

Anionic Surfactants: Dioctyl sulphosuccinate, Sodium lauryl sulphate, Decodecylmethyl sulphoxide etc**.**

Non Ionic Surfactants: Pluronic F127, Pluronic F68, etc.

Bile Salts: Sodium taurocholate, sodium deoxycholate, Sodium tauroglycocholate.

Miscellaneous chemicals: These include urea, a hydrating and keratolytic agent; N, N-dimethyl-mtoluamide; Calcium thioglycolate; Anticholinergic agentsSome potential permeation enhancers have recently been described but the available data on their effectiveness are sparseThese include eucalyptol, di-o-methyl-betacyclodextrin and soyabean casein.

Other Excipients:

Adhesives: Securing transdermal devices in place is essentialPressure-sensitive technology has been utilized to study skin up to this pointsticky substanceThe adhesive which is sensitive to pressure can belocated on the front or back of the device equipment and expanding outward.

Both adhesive systems should fulfill the following criteria

Must not inflame or cause sensitivity to the skinLack of balance in the typical skin microbiota.

Must stick firmly to the skin during the process dosing frequency without being disrupted by its placement tasks like washing, physical activity, etc.

Should be easily removed

Must not leave a residue on the skin that cannot be washed off.

Must have outstanding (close) connection with the skinat both the macro and micro level.

Backing Membrane: Backing membranes are pliable and adaptablethey create a strong connection with the drug reservoir, stopping prevent the drug from exiting the dosage form via the upper areaAuthorize to proceed with printingIt is impenetrable and provides protection for the productwhile being used on the skin such as metallic plastic laminate or plastic supporting with a pad that absorbs and a sealing base plate flexible adhesive foam pad made of aluminum foil Polyurethane material with a sealing base plate made of aluminum foil disc.

Release Liner: Storage is facilitated by the presence of a release linerloss of the drug that has moved into the sticky layer and pollutionIt is thus considered to be a component of the primary packaging material instead of being a component of the dose method for administering the medicationThe protective backing is made up of a primary layer that could be breathable (paper cloth) or an obstructive (polyethylene, polyvinylchloride) and a coating layer made of either silicon or Teflon for releasingAlternatively Polyester is one of the materials commonly used in the release liner for TDDSmetallic foil and laminated metal film.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

TYPES OF TRANSDERMAL PATCHES



Figure 4

Transdermal patches are classified based on their design, functionality, and therapeutic applicationsHere are some common types of transdermal patches:

1 Matrix-type patches:
- Contain drug reservoir surrounded by polymer matrix
- Drug diffuses through matrix to skin
- Examples: nicotine, fentanyl, and estradiol patches

2 Reservoir-type patches:
- Separate drug reservoir and adhesive layer
- Drug diffuses through rate-controlling membrane
- Examples: scopolamine and clonidine patches

3 Adhesive-type patches:
- Drug dispersed directly in adhesive
- No separate reservoir or matrix
- Examples: lidocaine and capsaicin patches

4 Ionophoretic patches:
- Use low electrical current to enhance drug delivery
- Examples: lidocaine and fentanyl patches for pain management

5 Electroporation patches:
- Use high-voltage pulses to create temporary skin pores
- Enhance drug delivery and vaccination efficacy

6 Microneedle patches:
- Use tiny needles to create micro-channels in skin
- Increase drug absorption and reduce invasiveness

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024



Figure 5: The microneedle-based patch
(**A**) solid; (**B**) hollow; (**C**) coated; (**D**) dissolving.

7 Thermal patches:
- Use heat to enhance drug delivery and skin permeability
- Examples: heat-activated lidocaine patches

8 Ultrasound patches:
- Use low-frequency ultrasound to enhance drug delivery
- Examples: ultrasound-mediated insulin delivery

Therapeutic Applications:
1 Pain management (e.g., lidocaine, fentanyl)
2 Smoking cessation (e.g., nicotine)
3 Hormone replacement therapy (e.g., estradiol)
4 Cardiovascular disease (e.g., clonidine)
5 Neurological disorders (e.g., rivastigmine)
6 Motion sickness (e.g., scopolamine)
7 Local anesthesia (e.g., lidocaine)
8 Vaccination (e.g., influenza, COVID-19)

RECENT ADANCEMENT OF TRANSDERMAL PATCH

Conventional transdermal patches have two primary functions: storing drugs and releasing themDespite its benefits, traditional patching poses several obstacles and disadvantages, such as restricted dosage or minimal releaseUntil now, there have been various improvements in transdermal drug deliveryThese features consist of new patch designs with improved drug sensing and release capabilities, increased drug loading, and improved drug penetration and releaseIn general, transdermal drug delivery is a lively area of research and development, with numerous promising new advancements on the way, as detailed later in this discussion.

Smart patches
Dissolving/Degradable patches
Three-Dimensional (3D)-Printed Patches
High Loading/Release Patches
Potential Application of Transdermal Patches
Transdermal Patches for Vaccination
Transdermal Patches for Gene Therapy
Transdermal Patches for Insulin Delivery
Transdermal Patches for Cardiovascular Diseases
Transdermal Patches for hormonal Deficiencies and Contraception
Transdermal Patches for Central Nervus System (CNS) Disorder

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

Transdermal Patches for Infectious Diseases.

CONDITION IN WHICH TRANDERMAL PATCHES ARE USED:

Transdermal patch is used when:

-When the patient has intolerable side effects (including constipation) and who is unable to take oral medication and is requesting an alternative method of drug delivery.

-Where the pain control might be improved by reliable administration this might be useful in patient with cognitive impairment or those who for other reason are not able to self-medicate with their analgesia.

CONDITION IN WHICH TRANDERMAL PATCHES ARE NOT USED:

The use of transdermal patch is not suitable when:

-Cure for acute pain is required

-Where rapid dose titration is required

-Where requirement of dose is equal to or less than 30 mg/24hrs.

PREPARATION OF TRANSDERMAL PATCHES

Transdermal drug delivery patches can be prepared by various methods

Mercury Substrate Method:

This technique involves dissolving the necessary drug quantitypredefined quantity of polymer solution together with Substance used to soften or increase the flexibility of plasticMix the solution above for a whileadequate time is required to create a uniform mixture and maintain it set aside until all air bubbles are completely removed before continuing poured into a glass ring positioned above the mercury A glass petri dish with a smooth topThe speed at which evaporation occurs controlling the solvent is done by covering it with an upside-down funnelcontainer for growing microorganismsThe desiccator is where the dried films should be stored.[63-67]

Circular Teflon Mould Method:

Polymers of different proportions are present in solutions frequently utilized ina solvent of organic originThe quantity of drug is measured and mixed in liquid form in half the amount of the identical organic solventSoftening agent incorporated into polymer solution for drugsThe complete contents need to be accounted for Get mixed and subsequently transferred into a round Teflon containerSolvent vaporization rate is regulated by placementGlass funnel inverted onto Teflon moldThe substance used for dissolving is permitted to dry out for 24 hoursThe dried coatings need to be kept in a desiccator.[68]

Glass Substrate Method:

The polymeric solutions are set aside to swellThe necessary amount of plasticizer and drug solution is includedand agitated for 10 minutesAdditionally, it is designated for certain purposesThe time needed to remove any trapped air is taken before pouring the Sanitize and ensure a petri dish is free of moistureThe solvent rate controlling evaporation by placing a glass funnel upside down over the dish used in laboratories for culturing microorganismsThe dried films are removed the next dayremoved and kept in a dehydration chamber.[69]

By Using IPM Membrane Method:

In this method drug is dispersed in a mixture of water and propylene glycol containing carbomer 940 polymers and stirred for 12 hrs in magnetic stirrerThe dispersion is to be neutralized and made viscous by the addition of triethanolamineBuffer pH 7.4 can be used in order to obtain solution gel, if the drug solubility in aqueous solution is very poorThe formed gel will be incorporated in the IPM membrane.[70].

By Using EVAC Membranes Method:

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

To get ready for the intended transdermal treatmentgel reservoir with 1% carbopol system, polyethylene (PE) EVAC membranes, consisting of ethylene vinyl acetate copolymer, are able to serve as membranes for controlling ratesIf the medication is not Propylene glycol, which can be dissolved in water, is utilized for the same purposesMaking gelMedicine is mixed into propylene glycolcarbopol resin is to be included in the solution mentioned aboveNeutralization is achieved through the use of a 5% weight/weight solution of sodium hydroxideThe gel form of the drug is applied onto a backing sheetA covering layer that spans the designated regionA controlling rate a membrane will cover the gel and the edges will be securedlocked through heat to achieve a device that is resistant to leaks.[71]

Aluminium Backed Adhesive Film Method

Transdermal drug delivery system has the potential to create unpredictable outcomesmatrices when the initial dose exceeds 10 mgThe aluminum-backed adhesive film technique is an appropriate optionChloroform is the preferred solvent for preparing the samesince the majority of drugs and adhesive can dissolve in a solution of chloroformThe chloroform dissolves the drugThe drug solution will have adhesive material added to itbroken downAn aluminum former customized specifically for the task is coated with aluminum foil with the edges sealed tightlycork cube.[72]

Asymmetric TPX Membrane Method

A model patch can be created using a heat-sealing methodpolyester film (1009 type, 3m) with a curvature of 1cm diameter serves as the supporting membraneSample of medication is providedpoured into the curved surface, protected by a TPX film Asymmetrical membrane made of poly(4-methyl-1-pentene) secured by a sticky substance.[73]

EVALUATION IN TEST OF TRANSDERMAL PATCH

Drug Excipients Interaction Studies:

The drug must be compatible with excipients to create a effective medicationIt is essential to identify any potential issues with the product to ensure its stabilityinteraction involving both physical and chemical elementsStudies examining interactions are conductedFrequently conducted using thermal analysis, FT-IR analyzing studies using UV and chromatographic methodstheir chemical and physical properties like testing, liquefying Warm-blooded animals, specific frequencies, and uptake maximum and so on

Water Vapor Tansmission Rate (WVTR) Studies: lass vials of the same size were utilized for transmissionThe building blocks of all living organisms are cellsThese transmission cells were cleaned completelythen heated in oven at 100 oC for a period of timeApproximately one gram cells were filled with anhydrous calcium chlorideThe polymer film of each was attached to the edgeThe cell structure is made up of various componentswere precisely measured and stored in a sealed desiccator holding a saturated potassium chloride solution within Water Vapor Transmission Rate = Final Weight –Initial Weight/ Time X AreIt is expressed as the number of grams of moisture gained/hr/cm.sq.

Thickness of the patch: The drug loaded's thicknessA digital is used to measure the patch at various pointsmeasures in micrometers to calculate the mean thicknessstandard deviation to guarantee consistency in thickness.

Skin Irritation Study: Irritation and sensitization of the skin Healthy rabbits can undergo testing(average weight 1.2 to 1.5 kg) The upper side of the rabbit is to be cleaned and have its hair removedprepare the dorsal surface by shaving and cleansing the areaRectified alcohol and the typical compositions may be utilizedplaced on the skinThe patch should be taken off in 24 hoursThe skin should be monitored and categorized into 5 categories every few hoursgrading according to the seriousness of the skin damage.

Flatness Test: Three vertical strips are going to be removed from each movie is positioned at a distinct location, such as one being in the middleone from the left side and another from the right edgeMeasure the length of each stripdifference in size due to unevenness in flatness constriction was assessed by calculating the percentage of constriction0% restriction is the same as 100% flatness.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

Drug content: A particular section of the patch must be designatedmixed in an appropriate liquid in a particular amountNext, the answer must pass through a filtering substance and analyze the drug composition using the appropriate technique (UV or)Technique of HPLCEvery value is the average of threeExamples.

Weight Uniformity: The patches that have been prepared need to be driedTesting will take place after the sample has been kept at a temperature of 60°C for a duration of 4 hoursA designated patch of land is meant to be sliced into various sections of the area and then measured in terms of weight electronic scaleThe mean weight and deviation is standard Calculations will be done based on the weights of each individual.

Folding Endurance: A piece of particular size needs to be slicedFolded in a uniform manner at a consistent location until it eventually fracturedThe film could be folded the same number of timesposition without tearing provided the worth of the bending endurance

Swellability: The 3.14 cm^2 patches were measured in weightplace into a petri dish with 10 ml of double distilled water and were permitted to drinkWeight gain has occurredthe patch was scheduled to be applied at specific time intervals, up to a certain point consistent weight was noted.
The degree of swelling (S) was calculated using the formula,
$S (\%) = Wt – Wo / Wo \times 100$
Where S is percent swelling
Wt is the weight of patch at time t and Wo is the weight of patch at time zero.

Moisture Loss: The films that are ready need to be measuredseparately and stored in a desiccator with appropriate care calcium chloride at a temperature of 40 degrees CelsiusThe films should be left for 24 hoursreassessed and calculated the amount of moisture lost as a percentage from the formula below

$$\% \text{ Moisture Loss} = [\text{Initial wt} – \text{Final wt}/ \text{Final wt}] \times 100$$

Percentage Moisture Uptake: The films that were measured have to be analyzedPlace in desiccators at room temperature for 24 hoursholding a fully saturated potassium chloride solution within in order to keep RH at 84%The films should be watched within 24 hoursweighed again to establish the moisture uptake percentage from the formula provided below.

Probe Tack Test: Weight is measured using a scale with units in grams During this examination, the point of a sterile probe was useda specified level of roughness is put in touch with sticky and when the probe is attached sticky substance The probe was then removedbreaks it in a mechanical way The amount of force needed to drag the object investigating the adhesive by moving away at a constant speed is noted Weight is measured in grams.

Percentage Elongation Break Test: The proportion The length must be observed to determine elongation breakright before the breaking point, there is an increase in the percentage of extensioncan be calculated using the formula provided below.

Tensile Strength: A modified pulley system is utilized to study the tensile strength of the fileThe system measures the force needed to break the film, providing valuable information about its tensile strength

Shear adhesion test: This test is conducted to assess the cohesive strength of the adhesive polymerIn this method, the adhesive-coated patch is applied over a smooth surface, and a specific weight is hung from the patch parallel to the surface The duration taken to pull off the patch from the surface measures its shear adhesion property, indicating the strength of the adhesive bond.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

Peel adhesion test: In this test, the force required to remove the patch from a surface is determinedThe patch is applied to a steel plate, and then it is pulled away at a 180-degree angle from the surfaceThe force needed to detach the patch is measured, providing information about its adhesive strength.

Rolling ball tack test: In this test, a steel ball with a diameter of 7/16 inch is rolled down on inclined plane with the horizontally placed patch facing upward, adhesive surface exposedThe ball roll down and travels a specific horizontal distance on the patchThe distance covered by the ball provides information about the tackiness or tack property of the adhesive patchTackiness is a adhesive's ability to quickly adhere to a surface upon contact.

Thumb tack test: Tackiness is determination by the force needed to separate a thumb or any object from an adhesive surface.

In-vitro drug release studies: The disk on top of the paddle USP apparatus V method can be used forevaluation of the drug's dissemination from the fabricated patches of landThe plan is to cut dry films of a specified thicknessexact form, measured and secured onto a glass surface with a sticky substanceThe glass plate was subsequently inserted into a 500-ml containerof the solution medium or phosphate buffer at a pH of 7.4 equipment was adjusted to a temperature of 32± 0.5°CThe paddle was later positioned 2.5 cm away from the glassplate spinning at a rate of 50 revolutions per minute5 milliliters of samples Fractions can be taken out at the right intervalsfor 24 hours and tested using a UV spectrophotometer or high-tech analysis machinehigh performance liquid chromatography (HPLC) technologyThe text needs to be provided in order to be paraphrasedAn experiment will be conducted three times and the average will be calculated calculating value is possible

In-vivo studies: The genuine representation comes from in-vivo assessmentsregarding the drug's effectivenessThe variables that are unable to be fully considered in in-vitro studies investigated through in-vivo experimentsAssessment of in vivo conditions TDDS can be performed by utilizing:
Models of animals
Volunteers who are human

Stability Studies: Experiments on stability are to be carried outbased on the ICH guidelines through storing the TDDS samples stored at a temperature of 40±0.5°C and a relative humidity of 75±5% for a period of 6 monthstext should be paraphrased while maintaining the same vocabulary and word countsamples were taken at intervals of 0, 30, 60, 90, and 180 daysexamine appropriately for the medication's ingredients.

LIMITATIONS FOR SELECTION OF TDDS

Not all drugs can be given using this methodpathway; the drug needs to possess certain favorable Physico-Chemical characteristics.
Unsuitable for medications that necessitate elevated plasma concentrations.
Inappropriate for medications causing skin irritationdermatitis caused by contact.
Inappropriate for medications with large molecular size.
Inappropriate for medications that experience metabolism while undergoing treatmentthe penetration of the skin.

II. CONCLUSION AND UPCOMEING OBSTACLES

Effective way to administer medication through the skina possible method to provide consistent administrations of numerous drugsA variety of medications can be administered Enhanced drug absorption with minimal adverse effects and complicationsAdvantages include affordability and simplicity of use A decade earlier, smoking cessation had been revolutionized by the nicotine patchpatients were undergoing treatment with nitroglycerin for anginaclonidine is used to treat high blood pressure, while scopolamine is for motion sicknessillness and estradiol for lack of estrogen, throughout patches are utilized by more than one million patients annuallyThe current method for delivering a drug product is through transdermal meansApproved in the form of oral dosage, enables the prevention of Metabolism that occurs

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

during the initial passage through the bodyeffective method for delivering medication through the skin, providing consistent and controlled absorptionA popular way to administer drugs through the skinNevertheless, the limitations of transdermal technologies are caused by fairly resistant layer of thick outer stratum corneum stratumScientists are working to overcome this obstacleInadequate permeability due to physical and chemical factors.

Recently, there have been numerous advancements in transdermal patch technology, such as the creation of intelligent, dissolvable/biodegradable, high-capacity/release, and 3D-printed patchesDespite the potential benefits of transdermal patches for drug delivery, challenges including self-inflicted toxicity from incorrect dosing, poor adhesion, low drug penetration, skin irritation, and patch failure must be addressedFurther research and development are necessary to enhance the safety and effectiveness of this delivery system.

REFERENCES

[1]. LV Allen NG Popovich C Howard AnselPharmaceutical dosage forms and drug delivery systems, 8th Edn.Wolter Kluwer PublishersNew Delhi20052989

[2]. P Kumar C Sankar B Mishra Delivery of macromolecules through skinIndian Pharm200453717

[3]. OA Al Hanbali HMS Khan M Sarfraz M Arafat S Ijaz A Hameed Transdermal patches: Design and current approaches to painless drug deliveryActa Pharm201969219715

[4]. Y Zhang J Yu AR Kahkoska J Wang J B Buse Z Gu Advances in transdermal insulin deliveryAdv Drug Deliv Rev2019139517010.1016/j.addr.2018.12.006

[5]. P De Vos MM Faas M Spasojevic J Sikkema Encapsulation for preservation of functionality and targeted delivery of bioactive food componentsInt Dairy J2010204292302

[6]. P Heifer TR Shultz Coupled feedback loops maintain synaptic long-term potentiation: A computational model of PKMzeta synthesis and AMPA receptor traffickingPLoS Comput Biol2018145100614710.1371/journal.pcbi.1006147

[7]. B Barry EM Aulton Transdermal drug deliveryThe science of dosage forms design, 2nd ednHarcourt publishersChurchill Livingstone, New York2002499533

[8]. AC Williams BW Barry Penetration enhancersAdv Drug Deliv Rev201264512818

[9]. Musselman M., Faden J., Citrome LAsenapine: An atypical antipsychotic with atypical formulations*TherAdvPsychopharmacol*2021;11:20451253211035269doi: 10.1177/20451253211035269[PMC free article] [PubMed] [CrossRef] [Google Scholar]

[10]. Musselman M., Faden J., Citrome LAsenapine: An atypical antipsychotic with atypical formulations*TherAdvPsychopharmacol*2021;11:20451253211035269doi: 10.1177/20451253211035269[PMC free article] [PubMed] [CrossRef] [Google Scholar]

[11]. Yamashita T., Ikeda T., Akita YComparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study) *JCardiol*2019;73:386–393doi: 10.1016/j.jjcc.2018.11.009[PubMed] [CrossRef] [Google Scholar]\

[12]. Transdermal buprenorphine (Butrans) for chronic pain*MedLettDrugs Ther*2011;53:31–32[PubMed] [Google Scholar]

[13]. James I.G., O'Brien C.M., McDonald C.JA randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain*JPain Symptom Manag*2010;40:266–278doi: 10.1016/j.jpainsymman.2010.01.013[PubMed] [CrossRef] [Google Scholar]

[14]. Smyth M., Haupt T.S., Gregoire M.CRetrospective Review of the Use of Transdermal Buprenorphine Patches (Butrans) in a Pediatric Population*JPalliatMed*2020;23:1094–1097doi: 10.1089/jpm.2019.0381[PubMed] [CrossRef] [Google Scholar]

[15]. Guo J.M., Shi X.X., Yang S.W., Qian Q.F., Huang Y., Xie Y.Q., Ou PEfficacy of clonidine transdermal patch in treatment of moderate to severe tic disorders in children*ChinJContempPediatr*2017;19:786–789doi: 10.7499/j.issn.1008-8830.2017.07.011[PMC free article] [PubMed] [CrossRef] [Google Scholar]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

[16]. Kang H., Zhang Y.F., Jiao F.Y., Guo X.Y., Gao X.MEfficacy of clonidine transdermal patch for treatment of Tourette's syndrome in children*ChinJContempPediatr*2009;11:537–539[PubMed] [Google Scholar]

[17]. Ke G.M., Wang L., Xue H.Y., Lu W.L., Zhang X., Zhang Q., Guo H.YIn vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children*BiolPharmBull*2005;28:305–310doi: 10.1248/bpb.28.305[PubMed] [CrossRef] [Google Scholar]

[18]. Song P.P., Jiang L., Li X.J., Hong S.Q., Li S.Z., Hu YThe Efficacy and Tolerability of the Clonidine Transdermal Patch in the Treatment for Children with Tic Disorders: A Prospective, Open, Single-Group, Self-Controlled Study*FrontNeurol*2017;8:32doi: 10.3389/fneur.2017.00032[PMC free article] [PubMed] [CrossRef] [Google Scholar]

[19]. Antihypertensive Patch Italian Study (APIS) Investigators One year efficacy and tolerability of clonidine administered by the transdermal route in patients with mild to moderate essential hypertension-A multicentre open label study*ClinAutonRes*1993;3:379–383doi: 10.1007/BF01829457[PubMed] [CrossRef] [Google

[20]. Cutler A.J., Suzuki K., Starling B., Balakrishnan K., Komaroff M., Castelli M., Meeves S., Childress A.CEfficacy and safety of dextroamphetamine transdermal system for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: Results from a pivotal phase 2 study.*JChild AdolescPsychopharmacol*2022;32:89doi: 10.1089/cap.2021.0107[PMC free article] [PubMed] [CrossRef] [Google Scholar]

[21]. Kim Y.H., Choi H.Y., Lim H.S., Lee S.H., Jeon H.S., Hong D., Kim S.S., Choi Y.K., Bae K.SSingle dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers*Drug DesDevTher*2015;9:1419–1426doi: 10.2147/DDDT.S78555[PMC free article] [PubMed] [CrossRef] [Google Scholar]

[22]. Yoon S.K., Bae K.S., Hong D.H., Kim S.S., Choi Y.K., Lim H.SPharmacokinetic evaluation by modeling and simulation analysis of a donepezil patch formulation in healthy male volunteers*Drug DesDevelTher*2020;14:1729doi: 10.2147/DDDT.S244957[PMC free article] [PubMed] [CrossRef] [Google Scholar]

[23]. Aguirre W., Chedraui P., Mendoza J., Ruilova IGabapentin vslow-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes*GynecolEndocrinol*2010;26:333–337doi: 10.3109/09513590903511539[PubMed] [CrossRef] [Google Scholar]

[24]. Clemente C., Caruso M.G., Berloco P., Buonsante A., Giannandrea B., Di Leo Aalpha-Tocopherol and beta-carotene serum levels in post-menopausal women treated with transdermal estradiol and oral medroxyprogesterone acetate*HormMetabRes*1996;28:558–561doi: 10.1055/s-2007-979852[PubMed] [CrossRef] [Google Scholar]

[25]. Zieman MThe introduction of a transdermal hormonal contraceptive (Ortho Evra/Evra) *FertilSteril*2002;77:S1–S2doi: 10.1016/S0015-0282(01)03274-5[PubMed] [CrossRef] [Google Scholar]

[26]. Zieman M., Guillebaud J., Weisberg E., Shangold G.A., Fisher A.C., Creasy G.WContraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: The analysis of pooled data*FertilSteril*2002;77:S13–S18doi: 10.1016/S0015-0282(01)03275-7[PubMed] [CrossRef] [Google Scholar]

[27]. Baumrucker S.JDuragesic (transdermal fentanyl) in hospice care*AmJHospPalliatCare*1996;13:13–15doi: 10.1177/104990919601300608[PubMed] [CrossRef] [Google Scholar]

[28]. Abramowicz M., Zuccotti G., Pflomm J.M., Daron S.M., Houst B.M., Zanone C.E., Dalton V.K., Epstein E.J., Hirsch J., Juurlink D.NA granisetron patch (sancuso) *MedLettDrugs Ther*2008;50:103–104; quiz p102 following 104[PubMed] [Google Scholar]

[29]. Howell J., Smeets J., Drenth H.J., Gill DPharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting*JOncolPharmPract*2009;15:223–231doi: 10.1177/1078155209104063[PubMed] [CrossRef] [Google Scholar]

[30]. Le T.N., Adler M.T., Ouillette H., Berens P., Smith J.AObservational Case Series Evaluation of the Granisetron Transdermal Patch System (Sancuso) for the Management of Nausea/Vomiting of

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

Pregnancy*AmJPerinatol*2017;34:851–855doi: 10.1055/s-0037-1598652[PubMed] [CrossRef] [Google Scholar]

[31]. Badoi D., Crauciuc E., Rusu L., Luca VTherapy with climara in surgical menopause*RevMedChirSocMedNatIasi*2012;116:828–833[PubMed] [Google Scholar]

[32]. Taggart W., Dandekar K., Ellman H., Notelovitz MThe effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara) *Menopause*2000;7:364–369doi: 10.1097/00042192-200007050-00010[PubMed] [CrossRef] [Google Scholar]

[33]. Desai M.J., Siriki R., Wang DTreatment of pain in Dercum's disease with Lidoderm (lidocaine 5% patch): A case report*Pain Med*2008;9:1224–1226doi: 10.1111/j.1526-4637.2008.00417.x[PubMed] [CrossRef] [Google Scholar]

[34]. Karmarkar A., Lieberman IManagement of complex regional pain syndrome type II using lidoderm 5% patches*BrJAnaesth*2007;98:261–262doi: 10.1093/bja/ael343[PubMed] [CrossRef] [Google Scholar]

[35]. Wokovich A.M., Shen M., Doub W.H., Machado S.G., Buhse L.FEvaluating elevated release liner adhesion of a transdermal drug delivery system (TDDS): A study of Daytrana methylphenidate transdermal system*Drug DevIndPharm*2011;37:1217–1224doi: 10.3109/03639045.2011.565773[PubMed] [CrossRef] [Google Scholar]

[36]. Chen H.K., Lan T.H., Wu B.JA double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients*EurArchPsychiatry ClinNeurosci*2013;263:75–82doi: 10.1007/s00406-012-0338-3[PubMed] [CrossRef] [Google Scholar]

[37]. (37) Perng R.P., Hsieh W.C., Chen Y.M., Lu C.C., Chiang S.JRandomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation*JFormosMedAssoc*1998;97:547–551[PubMed] [Google Scholar]

[38]. Rich J.DTransdermal nicotine patch for smoking cessation*NEnglJMed*1992;326:344–345[PubMed] [Google Scholar]

[39]. Dahlstrom C.G., Rasmussen K., Bagger J.P., Henningsen P., Haghfelt TTransdermal nitroglycerin (Transiderm-Nitro) in the treatment of unstable angina pectoris*DanMedBull*1986;33:265–267[PubMed] [Google Scholar]

[40]. Greco R., D'Alterio D., Schiattarella M., Boccia A., Greco L., Marsico FEfficacy of a new transdermal nitroglycerin patch (Deponit 10) for stable angina pectoris*AmJCardiol*1988;61:44E–51Edoi: 10.1016/0002-9149(88)90090-2[PubMed] [CrossRef] [Google Scholar]

[41]. Mammen M.V., Tripathi M., Chandola H.C., Tyagi A., Bais P.S., Sanjeev O.PComparison of Enhancement of Analgesic Effect of Intrathecal Neostigmine by Intrathecal Clonidine and Transdermal Nitroglycerin Patch on Bupivacaine Spinal Anesthesia*AnesthEssays Res*2017;11:993–997doi: 10.4103/aer.AER_68_17[PMC free article] [PubMed] [CrossRef] [Google Scholar]

[42]. Savonitto S., Motolese M., Agabiti-Rosei EAntianginal effect of transdermal nitroglycerin and oral nitrates given for 24 hours a day in 2,456 patients with stable angina pectorisThe Italian Multicenter Study*IntJClinPharmacolTher*1995;33:194–203[PubMed] [Google Scholar]

[43]. Archer D.F., Furst K., Tipping D., Dain M.P., Vandepol CA randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopauseCombiPatch Study Group*ObstetGynecol*1999;94:498–503doi: 10.1016/s0029-7844(99)00359-2[PubMed] [CrossRef] [Google Scholar]

[44]. Dull PTransdermal oxybutynin (oxytrol) for urinary incontinence*AmFamPhysician*2004;70:2351–2352[PubMed] [Google Scholar]

[45]. Ho CTransdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder*Issues EmergHealth Technol*2001;24:1–4[PubMed] [Google Scholar]

[46]. Kurz A., Farlow M., Lefevre GPharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: A review*IntJClinPract*2009;63:799–805doi: 10.1111/j.1742-1241.2009.02052.x[PMC free article] [PubMed] [CrossRef] [Google Scholar]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

[47]. Lefevre G., Pommier F., Sedek G., Allison M., Huang H.L., Kiese B., Ho Y.Y., Appel-Dingemanse SPharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects*JClinPharmacol*2008;48:246–252doi: 10.1177/0091270007312154[PubMed] [CrossRef] [Google Scholar]

[48]. Chatsis VRotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease*Issues EmergHealth Technol*2008;112:1–6[PubMed] [Google Scholar]

[49]. Jessen L., Kovalick L.J., Azzaro A.JThe selegiline transdermal system (emsam): A therapeutic option for the treatment of major depressive disorder*P T Peer-RevJFormulManag*2008;33:212–246[PMC free article] [PubMed] [Google Scholar]

[50]. Johnson P., Hansen D., Matarazzo D., Petterson L., Swisher C., Trappolini ATransderm Scop for prevention of motion sickness*NEnglJMed*1984;311:468–469doi: 10.1056/NEJM198408163110713[PubMed] [CrossRef] [Google Scholar]

[51]. Swaminathan S.K., Strasinger C., Kelchen M., Carr J., Ye W., Wokovich A., Ghosh P., Rajagopal S., Ueda K., Fisher J., et alDetermination of Rate and Extent of Scopolamine Release from Transderm Scop(R) Transdermal Drug Delivery Systems in Healthy Human Adults*AAPS PharmSciTech*2020;21:117doi: 10.1208/s12249-020-01658-4[PubMed] [CrossRef] [Google Scholar]

[52]. Bhasin S., Storer T.W., Asbel-Sethi N., Kilbourne A., Hays R., Sinha-Hikim I., Shen R., Arver S., Beall GEffects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels*JClinEndocrinolMetab*1998;83:3155–3162doi: 10.1210/jc.83.9.3155[PubMed] [CrossRef] [Google Scholar]

[53]. De Sanctis V., Vullo C., Urso L., Rigolin F., Cavallini A., Caramelli K., Daugherty C., Mazer NClinical experience using the Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major*JPediatrEndocrinolMetab*1998;11((Suppl3)):891–900[PubMed] [Google Scholar]

[54]. Buch A., Shen L., Kelly S., Sahota R., Brezovic C., Bixler C., Powell JSteady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara*Menopause*1998;5:107–112doi: 10.1097/00042192-199805020-00009[PubMed] [CrossRef] [Google Scholar]

[55]. Rozenbaum H., Birkhauser M., De Nooyer C., Lambotte R., Pornel B., Schneider H., Studd JComparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50)ITolerability, adhesion and efficacy*Maturitas*1996;25:161–173doi: 10.1016/S0378-5122(96)01068-7[PubMed] [CrossRef] [Google Scholar]

[56]. Youngkin E.QEstrogen replacement therapy and the estraderm transdermal system*Nurse Pract*1990;15:19–26, 31doi: 10.1097/00006205-199005000-00005[PubMed] [CrossRef] [Google Scholar]

[57]. Yie W,Chien, Novel Drug Delivery Systems, 2nd ed, MDekker, 2005, 50, 301-380.

[58]. Eseldin Keleb, Rakesh Kumar Sharma, Transdermal Drug Delivery System-Design and Evaluation, International Journal

[59]. Ankush I, Shembale, Useful Permeation Enhancers for Transdermal Drug Delivery A Review, IJPRD, 2010, 5, 1-6.

[60]. Brian W, Barry, Dermatological Formulations Percutaneous Absorption, 18, 95-126.

[61]. Hadgraft J.W, and Somers G.F, Review Article Percutaneous absorption, International Journal of Pharmaceutics, 2005, 305, 2-12

[62]. Gilbert S, Banker, Christopher T, Rhodes, Modern Pharmaceutics, 2nd Ed, Revised and Expanded, 40, 263-298

[63]. Mohamed Aqil, Yasmin Sultana and Asgar Ali, Matrix Type Transdermal Drug Delivery Systems of Metoprolol Tartrate, Invitro Characterization, Acta Pharm, 2003,53, 119-125.

[64]. Basubramanian V, Iyer and Ravindra C, Vasavada, Evaluation of Lanolin alcohol flims and Kinetics of Triamcinolone Acetonide Release, Journal of Pharmaceutical Sciences, 1979, 68(6),119-125.

[65]. Chowdary K.PR and Naidu R.A.S, Preparation and Evaluation of Cellulose Acetate Films as Rate Controlling Membranes for Transdermal use, Indian Drugs, 1991, 29 (7), 312-315.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, September 2024

[66]. Mamatha T, Venkateswara Rao J, Mukkanti K, Development of Matrix Type Transdermal Patches of Lercanidipine Hydrochloride, Physicochemical and in-vitro Characterization, DARU, 2010, 18 (1), 9 -16.

[67]. Sridevi S, Chary M.G, Krishna D.R, Prakash V, Diwan, Pharmacodynamic Evaluation of Transdermal Drug Delivery System of Glibenclamide in Rats, Indian Journal of Pharmacology, 2000, 32, 309-312.

[68]. Sharma Teja, Rawal Gaurav, Transdermal Therapeutic Systems, An overview, International Journal of Pharmaceutical & Biological Archives, 2011, 2(6),1581-158

[69]. Sharma Teja, Rawal Gaurav, Transdermal Therapeutic Systems, An overview, International Journal of Pharmaceutical & Biological Archives, 2011, 2(6),1581-1587.

[70]. Shalu Rani, Kamal Saroha, Navneet Syan, Transdermal Patches a successful tool in Transdermal Drug Delivery System: An overview, Der Pharmacia Sinica, 2011, 2 (5),17-29

[71]. Parthasarathy G, Bhaskar reddy K and Prasanth V.V, Formulation and Characterization of Transdermal Patches of Naproxen with various polymers, Internati

[72]. Shalu Rani, Kamal Saroha, Navneet Syan, Pooja Mathur, Transdermal Patches A Successful Tool In Transdermal Drug Delivery System: An overview, Der Pharmacia Sinica, 2011, 2 (5), 17-29.

[73]. Kamal Saroha, Bhavna Yadav, Benika Sharma, Transdermal Patch, A Discrete Dosage Form, International Journal of Current Pharma Research, 2011,3(3), 98-108.